Table 3.
Toxicity ≥ Grade 3 (CTCAE V 4.0) in Total Cohort
| Toxicity | Grade 3 | Grade 4 | Grade 5 | Grade 3, 4 or 5 Total (N=297) |
|---|---|---|---|---|
| Biochemical | 73a (24.6%) | |||
| Bilirubin | 35 (11.8%) | 4 (1.3%) | 0 | |
| AST/ALT | 41 (13.8%) | 0 | 0 | |
| ALP | 2(0.6%) | 0 | 0 | |
| Gastrointestinal | ||||
| Biliary | 1 (0.3%) | 1 (0.3%) | 1 (0.3%) | 3 (1.0%) |
| Luminal GI toxicity | 3 (1.0%) | 0 | 1 (0.3%) | 4 (1.3%) |
| Liver | ||||
| Ascites | 23 (7.7%) | 0 | 0 | 23 (7.7%) |
| Classic RILD | 0 (0%) | |||
| CP score decline ≥ 2 at 3 months after SBRT | 34 (15.9%) | |||
| ALBI Grade increase at 3 months after SBRT | 51 (21.2%) | |||
Toxicity reported includes acute and late toxicity at least possibly attributable to SBRT.
Some patients had more than one kind of biochemical toxicity.